MarketInOut Stock Screener Log In | Sign Up

Alkermes Plc

NASDAQ • Healthcare • Drug Manufacturers - Specialty & Generic • Quote as of 10/30/2026
Alkermes Plc stock price and volume chart

Company Profile

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization7,606.39 mln
Float163 mln
Earnings Date11/03/2026

EPS

0.38
Overpriced

P / E

119
Highly speculative

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-1.44
Manipulation likely

1-Year Forecast

56.21
Attractive

Relative Strength

91 / 100
Top performer

Business Description

Alkermes is an Irish biopharmaceutical company founded in 1987 that develops and sells medicines for serious mental health and neurological conditions, including schizophrenia, bipolar disorder, and opioid and alcohol dependence. Its approved treatments are sold primarily in the United States, with additional operations in Ireland and other markets. The company also licenses its drug delivery technology to other pharmaceutical firms, supporting their efforts to develop and manufacture their own products.

Key Fundamentals

EPS0.38
P/E119
ROE3.78
RPS10.05
ROIC5.56
ROA2.10
Interest Cover2.43
EBITDA, mln218
EV / EBITDA39.73
EV / EBIT55.38
Revenue, mln1,668
EV / Revenue5.19

Quote Details

Last 45.34
Change -0.03 (-0.07%)
Open 45.67
Volume 1,103,100
Turnover 50,014,556
Average Volume 1,864,186

Financial Ratios

Pre-Tax Profit Margin6
Leverage Ratio2.43
Current Ratio2.30
Price / Book4.11
Price / Cash Flow30.07
Price / Free Cash Flow34.84
Debt / Equity0.87
Price / Sales4.51
PEG Ratio1.96

Financial Strength

Altman Z-Score2.2
Piotroski F-Score 4 / 9
Beneish M-Score-1.44
1-Year Target Price56.21
Short Ratio7.67
Short % of Float15.73

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.92% 86 / 100   
1 Month 11.84% 93 / 100   
2 Months -14.01% 27 / 100   
6 Months 35.83% 94 / 100   
1 Year 44.17% 90 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog